"Raloxifene Hydrochloride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.
| Descriptor ID |
D020849
|
| MeSH Number(s) |
D02.455.426.559.389.150.700.900.775
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Raloxifene Hydrochloride".
Below are MeSH descriptors whose meaning is more specific than "Raloxifene Hydrochloride".
This graph shows the total number of publications written about "Raloxifene Hydrochloride" by people in this website by year, and whether "Raloxifene Hydrochloride" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 3 | 1 | 4 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Raloxifene Hydrochloride" by people in Profiles.
-
Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2019 09 03; 322(9):868-886.
-
Estrogen or raloxifene during postmenopausal weight loss: adiposity and cardiometabolic outcomes. Obesity (Silver Spring). 2014 Apr; 22(4):1024-31.
-
Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013 Apr 16; 158(8):604-14.
-
Results from a randomized trial of a web-based, tailored decision aid for women at high risk for breast cancer. Patient Educ Couns. 2013 Jun; 91(3):364-71.
-
Informed choice about breast cancer prevention: randomized controlled trial of an online decision aid intervention. Breast Cancer Res. 2013; 15(5):R74.
-
Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid. Breast Cancer Res Treat. 2011 Jun; 127(3):681-8.
-
Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Ann Intern Med. 2009 Nov 17; 151(10):703-15, W-226-35.
-
Use of raloxifene among women with a history of breast cancer. Breast Cancer Res Treat. 2006 Mar; 96(2):123-9.
-
Breast cancer risk reduction options: awareness, discussion, and use among women from four ethnic groups. Cancer Epidemiol Biomarkers Prev. 2006 Jan; 15(1):162-6.
-
Women's decision making about whether or not to use breast cancer chemoprevention. Women Health. 2005; 41(2):81-95.